Loading…
PAVmed Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in PAVM.
▼ -99.8% over 5Y.
today you would have $1.00▼ -99.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 10 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $6.63 | $18.84 | $123.60 | $216.00 | $1,107.00 | $954.00 | $540.00 | $432.90 | $1,028.25 | $3,105.00 | |
| P/E | — | — | 1.3x | — | — | — | — | — | — | — | — |
| P/S |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DCGODocGo Inc. | $0.40 | — | 0.3x | — | -107.79% | $39.32M |
| CRVOCervoMed Inc. | $2.60 | — | 1.5x | — | -107.62% | $39.31M |
| KPTIKaryopharm Therapeutics Inc. | $1.75 | — | — | — | — | $39.69M |
| ELUTElutia Inc | $0.88 | — |
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Company description provided by Yahoo Finance.
| 125.3x |
| 596.1x |
| 3.5x |
| 15.1x |
| 125.3x |
| 431.3x |
| — |
| — |
| — |
| — |
| — |
| P/B | 3.5x | 1.2x | — | — | — | 3.5x | 92.2x | — | — | — | — |
| EPS | -$5.63 | $14.90 | -$274.80 | -$450.90 | -$292.50 | -$324.00 | -$243.00 | -$364.50 | -$319.50 | -$198.00 |
| Profit margin | -2567.00% | 564.79% | 1326.37% | -2567.00% | -23602.92% | -10069.40% | — | — | — | — | — |
| ROE | -81.64% | 1.18% | — | — | — | -81.64% | -1807.81% | — | — | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 2.5x |
| — |
| — |
| $38.97M |
| ACTUActuate Therapeutics Inc | $1.66 | — | 40.4x | — | — | $39.74M |
| CPHIChina Pharma Holdings Inc | $0.90 | — | 1.0x | — | -20.99% | $38.9M |